Fosun Pharma: Transaction Cap Adjusted Amid Profit Growth Outlook

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has increased its annual cap for products to be provided by Fosun International and/or its associates to the group for the year ending December 31, 2025. The original annual cap of RMB70 million has been raised to a revised cap of RMB90 million. This adjustment is to meet demand for further business development in the last quarter of 2025, where additional transactions for services provided by Fosun International are anticipated.

The revision ensures that the original annual cap will sufficiently cover relevant transactions under the Fosun International Mutual Supply Framework Agreement. For the nine months ended September 30, 2025, transaction amounts for services provided by Fosun International and/or its associates to the group totaled RMB59.14 million, representing 84% of the original annual cap.

According to Hong Kong Listing Rules, the revised annual cap is subject to reporting, announcement, and annual review requirements but is exempt from independent shareholders' approval, as it represents more than 0.1% but less than 5% of the highest applicable percentage ratio. The board, including independent non-executive directors, considers the revised cap to be fair, reasonable, and in the interests of the group and its shareholders.